A two piece adapter for extrusion of cylindrical core-shell structures using conventional biomedical needles includes first and second adapter pieces. The first adapter piece includes first and second (core and shell) inlet ports. The core inlet port leads directly to a male Luer fitting attachable to a core needle and surrounded by a threaded chamber. The shell inlet port is led, via a side chamber, into the side of the threaded chamber. The second adapter piece attaches to the bottom of the threaded chamber and is configured to attach to a shell needle, so that the shaft of the core needle sits inside the shaft of the shell needle.

An attachable needle assembly (102) for use on a medication delivery pen (104), the needle assembly (102) comprising a housing (110) enclosing a hub (106) having a communication needle (108) configured to engage the medication delivery pen (104) and pierce a reservoir septum of the medication delivery pen (104), a communication septum (172, 176) of the needle assembly (102) defining a septum chamber (180, 182) that is in fluid communication with the communication needle (108), a plurality of needles (118) disposed in the communication septum (172, 176), a follower ring (130) that determines which needle (124) of the plurality of needles (118) is to be selected, and a snap ring (136) that exposes the selected needle (124) and moves the selected needle (124) in fluid communication with the septum chamber (180, 182), wherein when the housing (110) is in a first position, the plurality of needles (118) is not exposed, and when the housing (110) is in a second position, the selected needle (124) is in fluid communication with the septum chamber (180, 182) and exposed for medicament delivery.

Systems for treating a targeted volume of muscle tissue to inhibit heterotopic ossification (HO) employ a delivery device including a reservoir containing a neuromuscular inhibitor and an injector assembly. The injector assembly can include an arrangement of needles and an injector operable to pass the neuromuscular inhibitor from the reservoir through the needles. The injector assembly can be configured to eject predetermined aliquots of a therapeutic dose of the neuromuscular inhibitor. The injector assembly can be shaped to compliment a targeted volume of muscle tissue within a larger volume of muscle tissue. The delivery of the aliquots can result in a therapeutic distribution of the therapeutic dose of neuromuscular inhibitor within the targeted volume of muscle tissue that is sufficient to prevent formation of an HO lesion but insufficient to induce paralysis of the larger volume of muscle tissue.

An image-guided lumbar puncture aspiration and injector system. The system includes an auto-injection device having a housing, at least one syringe having a fluid, a controller, a processor, a memory, and a display. An imaging device is communicatively coupled to the auto-injection device and captures images of a lumbar puncture area of a patient to be displayed on the display of the auto-injection device, helping identify a location for a lumbar puncture procedure. A needle assembly is coupled to the at least one syringe of the auto-injection device. An outer needle is adapted to be inserted into a location of the lumbar puncture area identified by the imaging device, and an inner needle is adapted to be inserted into the dura of the patient. The outer sheath needle protects the inner needle from contaminants. The controller operates the auto-injection device based on a programmed infusion and aspiration profile.

An intravascular sensor assembly including a flexible elongate member having a longitudinal axis (LA) is provided. The sensor assembly includes a first engagement feature proximal to a distal end of the flexible elongate member; a core member disposed inside a lumen of the flexible elongate member, the core member configured to translate within the flexible elongate member along the LA proximal to the first engagement feature; and a component holding a sensor circuit, the component fixedly secured to a distal end of the core member such that the mounting structure translates along the LA of the flexible elongate member with the core member. A system and a method for performing measurements using a sensor as above are also provided.

An intravascular sensor assembly including a flexible elongate member having a longitudinal axis (LA) is provided. The sensor assembly includes a first engagement feature proximal to a distal end of the flexible elongate member; a core member disposed inside a lumen of the flexible elongate member, the core member configured to translate within the flexible elongate member along the LA proximal to the first engagement feature; and a component holding a sensor circuit, the component fixedly secured to a distal end of the core member such that the mounting structure translates along the LA of the flexible elongate member with the core member. A system and a method for performing measurements using a sensor as above are also provided.

An injector may include a container having a wall with an interior surface defining a closed sterile reservoir filled with a drug product. The injector may also include a fluid delivery system comprising a sterile container needle that is in fluid communication with the container in a delivery state, but may or may not be in fluid communication with the container in a storage state. Further, the injector may include an actuator that is adapted to move the container needle from the storage state to the delivery state.

Methods of protecting muscle tissue from heterotopic ossification employ targeted deliveries of a neuromuscular inhibitor. A method of protecting muscle tissue from heterotopic ossification includes identifying a volume of muscle tissue that is susceptible to heterotopic ossification. A first aliquot of a therapeutic dose of a neuromuscular inhibitor is delivered at a first delivery site within the volume of muscle tissue. A second aliquot of the therapeutic dose is delivered at a second delivery site within the volume of muscle tissue. The first and second delivery sites are separated by a distance to distribute the therapeutic dose within the targeted volume of muscle tissue.

A device for injecting a therapeutic agent into an ocular implant at least partially implanted in an eye including an injection lumen providing a pathway for injecting the therapeutic agent into the implant; an outlet lumen providing a pathway for pre-existing fluid in the ocular implant to exit the implant; and a collection chamber fluidly coupled to the outlet lumen that provides a first fluid outflow resistance and a second fluid outflow resistance. The first fluid outflow resistance is lower than a first resistance to outflow of the implant. The second fluid outflow resistance is greater than a force imparted onto the implant by intraocular pressure of the eye. Injection of therapeutic agent into the implant via the injection lumen causes the pre-existing fluid to exit the implant and enter the collection chamber via the outlet lumen and causes a second pre-existing fluid to displace from the collection chamber.

An approach is provided for delivering therapeutic materials to an intervertebral disc via a sub-ligamentous space. The approach includes positioning a tool at an interface of a longitudinal ligament and an outer surface of the intervertebral disc, in which the interface is the sub-ligamentous space. The tool may include a first needle and a second needle housed within the first needle. An insertion end of the first needle may include a shallow beveled end. The approach includes inserting the insertion end of the first needle into the sub-ligamentous space. The approach includes deploying the second needle from within the first needle into at least one of an annulus and a nucleus of the intervertebral disc. The approach includes delivering the therapeutic materials to the at least one of the annulus and the nucleus.